Effects of oral magnesium sulphate on colonic motility in patients with the irritable bowel syndrome.
Magnesium sulphate, a substance known to cause release of cholecystokinin (CCK) from the small intestinal mucosa, was given by mouth (dose 0.1g/kg in 150 ml water) to 20 patients with the irritable bowel syndrome. A rapid increase in colonic segmental motor activity (onset within two to six minutes in most cases) was seen (percentage activity increased from 16.2 to 23.7 p<0.05; mean wave amplitude from 7.1 to 9.1 cm H(2)O, NS; motility index from 144 to 259, p<0.01). This increase was most marked in 10 patients who complained of attacks of abdominal pain after food (16.1 to 29.8%, p<0.01; 6.8 to 9.6 cm H(2)O, p<0.05; 135 to 350, p<0.05), and after the magnesium sulphate three of these patients experienced an attack of their usual pain. These findings provide further evidence that ;functional' abdominal pain after food may in some cases be related to an exaggerated intestinal motor response to cholecystokinin.
D002766:Cholecystokinin / Q000378:metabolism; D003106:Colon / Q000187:drug effects*; D012809:Colon, Sigmoid / Q000378:metabolism; D003109:Colonic Diseases, Functional / Q000503:physiopathology*; D004435:Eating; D005215:Fasting; D005769:Gastrointestinal Motility / Q000187:drug effects*; D006801:Humans; D008278:Magnesium Sulfate / Q000494:pharmacology*; D010146:Pain; D011312:Pressure; D012812:Sigmoidoscopy
D008278:Magnesium Sulfate; D002766:Cholecystokinin